NCT04571411 is a clinical trial of CBC in Scorpion Stings, sponsored by Assiut University.

Who is sponsoring NCT04571411?

NCT04571411 is sponsored by Assiut University.

What drugs are being tested in NCT04571411?

Interventions in NCT04571411: CBC.

What condition does NCT04571411 study?

NCT04571411 studies Scorpion Stings.

Is NCT04571411 still recruiting?

NCT04571411 is currently status unknown. Last updated 14 October 2020.

Last reviewed 2020-10-14 · How we verify

NCT04571411

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Severity of Scorpion Sting in Relation to Hematological Parameters

Status unknown Last updated 14 October 2020

What this trial tests

trial testing CBC in Scorpion Stings in 100 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
1 March 2023

1 September 2023

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 December 2020
Primary completion	1 March 2023
Estimated completion	1 September 2023

Drugs / interventions tested

Conditions studied

Scorpion Stings — all drugs for Scorpion Stings →

Sponsor

Assiut University

Who can join

Adults 0 Months to 18, any sex, with Scorpion Stings. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CBC

Trials testing the same drug.

NCT07479563 — Modified Shock Index · not yet recruiting
NCT06568913 — The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to S · NA · recruiting
NCT06491667 — NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction · recruiting
NCT06294483 — Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. · unknown
NCT05997108 — Platelet and Red Blood Cell Volume Indices as Inflammatory Biomarkers in Ankylosing Spondylitis · unknown

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04571411 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 14 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04571411.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing